Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery

Immune checkpoint therapy for non-small-cell lung cancer: an update

(2016) Bing Xia et al.   Immunotherapy

The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non–Small Cell Lung Cancer

(2016) Roy M. Bremnes et al.   Journal of Thoracic Oncology

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Prognostic Value of 18F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis

(2016) Jing Liu et al.   PLoS One

The Non–Small Cell Lung Cancer Immune Contexture. A Major Determinant of Tumor Characteristics and Patient Outcome

(2015) Romain Remark et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy

(2015) R. Tavare et al.   CANCER RESEARCH

Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies

(2015) S. Heskamp et al.   CANCER RESEARCH

Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer

(2015) Anders Josefsson et al.   CANCER RESEARCH

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

(2015) Chih-Hao Chang et al.   CELL

Immune Checkpoint Modulation for Non-Small Cell Lung Cancer

(2015) J.-C. Soria et al.   CLINICAL CANCER RESEARCH

18F-FDG PET/CT Mean SUV and Metabolic Tumor Volume for Mean Survival Time in Non–Small Cell Lung Cancer

(2015) Ercan Kurtipek et al.   CLINICAL NUCLEAR MEDICINE

The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis

(2015) A. Wang et al.   EJSO

The Warburg effect in mycobacterial granulomas is dependent on the recruitment and activation of macrophages by interferon-γ

(2015) Rui Appelberg et al.   IMMUNOLOGY

Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung Cancer

(2015) Kurt A. Schalper et al.   JNCI-Journal of the National Cancer Institute

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung Cancer

(2015) Kurt A. Schalper et al.   JNCI-Journal of the National Cancer Institute

Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma

(2015) Giovanni Francesco Castino et al.   OncoImmunology

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

(2015) Lars Henning Schmidt et al.   PLoS One

Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer

(2015) Jiabei He et al.   Scientific Reports

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

(2014) A D'Incecco et al.   BRITISH JOURNAL OF CANCER

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer

(2014) Satoshi Takeuchi et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0

(2014) Ronald Boellaard et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Tumor-Associated Macrophages: From Mechanisms to Therapy

(2014) Roy Noy et al.   IMMUNITY

Immunotherapy in the treatment of non-small cell lung cancer

(2014) Raghav Sundar et al.   LUNG CANCER

The Warburg effect then and now: From cancer to inflammatory diseases

(2013) Eva M. Palsson-McDermott et al.   BIOESSAYS

A “Big Data” View of the Tumor “Immunome”

(2013) Nicholas P. Restifo   IMMUNITY

The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures

(2013) Jérôme Galon et al.   IMMUNITY

Metabolic Pathways in Immune Cell Activation and Quiescence

(2013) Erika L. Pearce et al.   IMMUNITY

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

(2013) Charles Butts et al.   LANCET ONCOLOGY

Innate and adaptive immune cells in the tumor microenvironment

(2013) Thomas F Gajewski et al.   NATURE IMMUNOLOGY

Immune Responses to Cancer: Are They Potential Biomarkers of Prognosis?

(2013) Theresa L. Whiteside   Frontiers in Oncology

Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment

(2012) Douglas Hanahan et al.   CANCER CELL

Natural Innate and Adaptive Immunity to Cancer

(2011) Matthew D. Vesely et al.   Annual Review of Immunology

Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer

(2011) Shengri Liao et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Increased Levels of Tumor-Infiltrating Lymphocytes are Associated with Improved Recurrence-Free Survival in Stage 1A Non-Small-Cell Lung Cancer

(2011) Zachary D. Horne et al.   JOURNAL OF SURGICAL RESEARCH